Gilead Sciences Enters Voluntary Licensing Agreements for Experimental Ebola Treatment Obeldesivir

Gilead Sciences (GILD) has entered into royalty-free voluntary licensing agreements with three generic manufacturers to facilitate the potential production of obeldesivir. The experimental antiviral is designed to treat Bundibugyo virus disease, a form of Ebola. The initiative specifically targets low- and lower-middle-income countries to improve access to medical countermeasures. While the drug candidate remains in the experimental stage, these pacts establish a framework for manufacturing scalability in underserved regions.

By https://seekingalpha.com/user/53161691/bio · Seeking Alpha ·

Gilead Sciences Enters Voluntary Licensing Agreements for Experimental Ebola Treatment Obeldesivir

Tickers: $GILD

Topics: Ebola treatment global health licensing agreement pharmaceuticals

Read the full article at Seeking Alpha

More World news